Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab

The aim of the present study was to assess the expression of epithelial-mesenchymal transition biomarkers (E-cadherin and vimentin) and their potential significance as prognostic markers in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) enrolled in the INNOVATIONS trial,...

Descripción completa

Detalles Bibliográficos
Autores principales: Villalobos, Matthias, Czapiewski, Piotr, Reinmuth, Niels, Fischer, Jürgen R., Andreas, Stefan, Kortsik, Cornelius, Serke, Monika, Wolf, Martin, Neuser, Petra, Reuss, Alexander, Schnabel, Philipp A., Thomas, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507446/
https://www.ncbi.nlm.nih.gov/pubmed/31186697
http://dx.doi.org/10.3892/ol.2019.10153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507446/
https://www.ncbi.nlm.nih.gov/pubmed/31186697
http://dx.doi.org/10.3892/ol.2019.10153

Ejemplares similares